74.10
-0.05 (-0.07%)
| Previous Close | 74.15 |
| Open | 74.16 |
| Volume | 4,671,487 |
| Avg. Volume (3M) | 2,829,144 |
| Market Cap | 16,492,178,432 |
| Price / Earnings (TTM) | 29.76 |
| Price / Earnings (Forward) | 16.39 |
| Price / Sales | 4.15 |
| Price / Book | 3.31 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | 13.83% |
| Operating Margin (TTM) | 22.17% |
| Diluted EPS (TTM) | 2.38 |
| Quarterly Revenue Growth (YOY) | -1.20% |
| Quarterly Earnings Growth (YOY) | -18.50% |
| Total Debt/Equity (MRQ) | 54.80% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 1.13 B |
| Levered Free Cash Flow (TTM) | 775.88 M |
| Return on Assets (TTM) | 6.92% |
| Return on Equity (TTM) | 11.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bullish | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Hologic, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 102.61% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Argus Research, 21.46%) | Buy |
| Median | 78.00 (5.26%) | |
| Low | 76.00 (Morgan Stanley, 2.56%) | Hold |
| 76.00 (Stephens & Co., 2.56%) | Hold | |
| Average | 79.14 (6.80%) | |
| Total | 2 Buy, 5 Hold | |
| Avg. Price @ Call | 72.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 11 Nov 2025 | 76.00 (2.56%) | Hold | 74.60 |
| Mizuho | 23 Oct 2025 | 78.00 (5.26%) | Hold | 73.89 |
| JP Morgan | 22 Oct 2025 | 78.00 (5.26%) | Hold | 73.93 |
| Stephens & Co. | 22 Oct 2025 | 76.00 (2.56%) | Hold | 73.93 |
| 18 Sep 2025 | 78.00 (5.26%) | Buy | 68.27 | |
| Leerink Partners | 21 Oct 2025 | 78.00 (5.26%) | Hold | 73.98 |
| Evercore ISI Group | 07 Oct 2025 | 78.00 (5.26%) | Buy | 67.73 |
| Argus Research | 19 Sep 2025 | 90.00 (21.46%) | Buy | 66.33 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |